The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis.
Several studies examined a possible link between multidrug resistance-associated protein 2 (ABCC2) gene variants and the risk of resistance to antiepileptic drugs (AEDs) in epilepsy, but the results were contradictory. In this study, a meta-analysis was conducted to assess the relevance of ABCC2 common variants (c.-24C>T, c.1249G>A, c.3972C>T) with the response risk of AEDs. We searched Embase, PubMed, the Cochrane Library and CNKI databases for case-control studies published through May 2016 that evaluated the role of ABCC2 gene variants in pharmacoresistance to AEDs. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated to assess the strength of associations between the ABCC2 c.-24C>T, c.1249G>A and c.3972C>T variants and the risk of resistance to AEDs using an allele frequency model, dominant model and recessive model. Subgroup analyses were performed by ethnicity and the definition of drug-resistance. A total of 13 published studies involving 4300 patients (2261 patients with drug-resistant epilepsy and 2039 controls with drug-responsive epilepsy) met the selection criteria. We observed that the variant c.-24C>T was associated with a significantly increased risk of AED resistance (TT+CT vs CC: OR=1.24, 95%CI=1.06-1.46, p=0.009; TT vs CT+CC: OR=1.90, 95%CI=1.31-2.76, p=0.0008; T vs C: OR=1.27, 95%CI=1.11-1.46, p=0.0006). However, we identified no significant association of the ABCC2 c.1249G>A, c.3972C>T variants and haplotypes with the response to anticonvulsant drug in the overall population. In summary, these observations suggest that the ABCC2 c.-24C>T polymorphism is a likely risk factor for resistance to AEDs.
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Hospital Pharmacy, Central South University, Changsha 410008, China.
Long
L
Qian
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Hospital Pharmacy, Central South University, Changsha 410008, China.
Shu
S
Fang
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Hospital Pharmacy, Central South University, Changsha 410008, China.
Yuan-Liang
YL
Yan
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Hospital Pharmacy, Central South University, Changsha 410008, China.
Shuang-Shuang
SS
Zeng
Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhi-Jie
ZJ
Xu
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Hospital Pharmacy, Central South University, Changsha 410008, China. Electronic address: gongzhicheng2013@163.com.
Zhi-Cheng
ZC
Gong
D000927:Anticonvulsants / Q000627:therapeutic use*; D004351:Drug Resistance / Q000235:genetics*; D004827:Epilepsy / Q000188:drug therapy* / Q000235:genetics; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
D000927:Anticonvulsants; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins; C000715087:ABCC2 protein, human
ABCC2; Antiepileptic drugs; Epilepsy; Meta-analysis; Polymorphism